Journal article
Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study
Abstract
AIMS: In Europe, the approved rivaroxaban dose for stroke prevention in patients with atrial fibrillation (AF) is 20 mg once daily (o.d.), with 15 mg o.d. recommended in patients with creatinine clearance (CrCl) 15-49 mL/min. Non-recommended doses are prescribed in real-world practice. This analysis of the XANTUS study assessed outcomes associated with non-recommended dosing and patient characteristics that may have impacted dose choice.
Authors
Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG; Camm AJ
Journal
European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 5, No. 2, pp. 70–79
Publisher
Oxford University Press (OUP)
Publication Date
April 1, 2019
DOI
10.1093/ehjcvp/pvy041
ISSN
2055-6837